PCM
ALDR

Peregrine Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Peregrine Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-416,052
Closed -$8.82M – 259
2017
Q1 		$8.82M Buy
416,052
+63,643
+18% +$1.41M 0.22% 194
2016
Q4 		$7.33M Buy
352,409
+6,000
+2% +$156K 0.19% 233
2016
Q3 		$11.4M Buy
+346,409
New +$10.5M 0.3% 139

Other funds holding ALDR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Peregrine Capital Management's ALDR Position: Q2 2017 in Review

Peregrine Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q2 2017, closing a stake of 416,052 shares — an estimated $8.82M sold.

Peregrine Capital Management first reported a position in ALDR in Q3 2016 and held it in 3 quarters. The position peaked at $11.4M in Q3 2016. 128 funds tracked by Wall St. Rank hold ALDR as of Q2 2017.

  • Peregrine Capital Management reported no remaining Alder Biopharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Peregrine Capital Management sold 416,052 Alder Biopharmaceuticals shares in Q2 2017, an estimated $8.82M.
  • Peregrine Capital Management first reported a position in Alder Biopharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Peregrine Capital Management's Alder Biopharmaceuticals position peaked at $11.4M in Q3 2016.
  • 128 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q2 2017.

Based on Peregrine Capital Management's 13F filing for Q2 2017, filed 19 Jul 2017.